NCT05200923 · MedtronicNeuro
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
(PEER 2)
What this study is about
To collect physiological signals at several timepoints during the therapy evaluation period.
View original scientific description
To collect physiological signals at several timepoints during the therapy evaluation period.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Overactive Bladder Criteria Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\
- requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any OAB medication from baseline diary through the end of therapy evaluation
- For subjects with urinary urge incontinence, have a diagnosis of OAB as demonstrated on a voiding diary by having a minimum of 3 episodes of urinary urge incontinence in the first 72 hours (Episodes must have a mild, moderate, or severe degree of urgency to meet this criterion) of the voiding diary.
- For subjects with urinary frequency, have a diagnosis of OAB as demonstrated on a voiding diary with greater than or equal to 8 urgency frequency episodes per day within the first 72 hours of the voiding diary. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Non-Obstructive Urinary Retention Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant for labeled indication\
- requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any NOUR medication from baseline diary through the end of therapy evaluation
- Have a diagnosis of non-obstructive urinary retention with an elevated postvoid residual (PVR) that has persisted for at least six months and is documented on two or more separate occasions. Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study. Fecal Incontinence Inclusion Criteria
- 18 years of age or older
- Candidate for or undergoing Medtronic InterStim lead implant labeled indication\
- requiring an advanced evaluation
- Willing and able to provide signed and dated informed consent
- Willing and able to independently and accurately complete diaries, questionnaires, attend visits, and comply with the study protocol
- Willing to maintain current regimen (dosage and frequency) of any FI medication from baseline diary through the end of therapy evaluation
- Have a diagnosis of fecal incontinence as demonstrated by 3-day a bowel diary as greater than or equal to 1 incontinent episode of more than staining (i.e., either slight, moderate, or severe soiling) Note\*: Candidate for or undergoing a Medtronic InterStim lead implant for labeled indication means that a clinical decision has already been made between a physician and the patient to undergo Medtronic Interstim lead implant to treat the subject's condition. This decision is to be made prior to discussing with the patient whether to enroll in the study.
Exclusion criteria
- Overactive Bladder Criteria Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- History of diabetes unless the diabetes is well-controlled through diet and/or medications
- Have symptomatic urinary tract infection (UTI)
- Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
- Treatment of voiding behavior with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Non-Obstructive Urinary Retention Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- History of diabetes unless the diabetes is well-controlled through diet and/or medications
- Have symptomatic urinary tract infection (UTI)
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture)
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements Fecal Incontinence Exclusion Criteria
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results (co-enrollment in an interventional study is only allowed when documented pre-approval is obtained from the Medtronic study manager or designee)
- Implanted with a neurostimulator, pacemaker or defibrillator
- Pelvic floor muscle dysfunction due to surgical intervention or injury
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury (e.g., paraplegia)
- Have uncorrected high grade internal rectal prolapse
- Treatment of symptoms with tibial neuromodulation therapy in the last 3 months
- Have knowledge of planned magnetic resonance imaging (MRIs) during the therapy evaluation portion of the study
- Have knowledge of planned shortwave diathermy, microwave diathermy, or therapeutic diathermy
- Women who are pregnant or planning to become pregnant
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements
Where
- Indianapolis, Indiana
- New Orleans, Louisiana
- Rochester, Minnesota
- Cleveland, Ohio
- Hilliard, Ohio
- Edinburg, Texas
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 3, 2026 · Source of record for eligibility and locations